According to Interfax News, the’Russian Direct Investment Fund’ (RDIF), which is in charge of supporting the development of Sputnik V vaccine and producing and supplying it overseas, tweeted, “If you use the Sputnik V vaccine for the second dose of AZ vaccine (AZ), “There is no need to wait for three months for the vaccination,” he said. “A clinical trial of this method (combined vaccination method) has already begun.”
He did not comment on specific details such as the place of the combined vaccination test.
RDIF said earlier this month that Azerbaijan, the former Soviet Union, had approved a clinical trial for a combination of Sputnik V and AstraZeneca vaccines earlier this month.
The clinical trial is expected to be conducted in the United Arab Emirates (UAE) and Saudi Arabia following Azerbaijan.
In November of last year, Russia proposed a conjugate vaccination test for AstraZeneca, and consensus was reached after AZ accepted the proposal.
Both Sputnik V and AZ vaccines are carrier (vector) vaccines made by inserting the Corona 19 virus gene into another virus (carrier) that is harmless to the human body.
Sputnik V uses adenovirus types 5 and 26, which are common cold viruses, as vectors for two inoculations.
On the other hand, the Corona 19 vaccine developed by AstraZeneca with Oxford University in the UK is based only on adenovirus type 5.
It is reported that the Sputnik V and AstraZeneca combined vaccination test will be conducted for 6 months with 100 volunteers each in three countries, including Azerbaijan.
Both sides are known to be injecting the first dose with the AZ vaccine using adenovirus type 5 as a vector, and after a certain period of time, a second injection of the adenovirus type 26 Sputnik V vaccine is known to be conducted.
Russia and the UK expect to increase the immune effect of the vaccine through a combined vaccination of each vaccine.
[연합뉴스]
Copyrights ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited